3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
10
Lymphoid
10
Gastrointestinal
7
Thoracic
3
Plasma cell
3
Dermatologic
3
CNS
3
Breast
3
Myeloid
2
Head & Neck
2
Gynecologic
2
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Other neoplasm
1
Genitourinary
1
Conditions
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Cisplatin
145
pembrolizumab
129
Carboplatin
125
Injections
108
Pemetrexed
97
Paclitaxel
97
Gemcitabine
85
Irinotecan
75
Nivolumab
71
Cyclophosphamide
71
Docetaxel
68
Bevacizumab
57
Oxaliplatin
49
Fluorouracil
48
atezolizumab
46
Capecitabine
46
Etoposide
42
Leucovorin
41
tislelizumab
40
toripalimab
36
fludarabine
32
Ipilimumab
30
Drug Therapy
30
Topotecan
29
durvalumab
28
Vincristine
27
Early Intervention, Educational
27
Radiotherapy
26
Interviews as Topic
26
Specimen Handling
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Influenza Vaccines
×
Other solid neoplasm
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled